-99.9%
SQQQ vs MRNA
+554.4%
-654.3%
-99.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -2.6% | +5.4% | -8.0% | -1.8% |
| 7D | +1.8% | -1.1% | +2.9% | +1.7% |
| 30D | +4.2% | +126.1% | -122.0% | +27.1% |
| 3M | -3.3% | +190.0% | -193.3% | +27.7% |
| 6M | -43.6% | +157.2% | -200.9% | -26.2% |
| YTD | -41.9% | +388.2% | -430.1% | -9.0% |
| 1Y | -50.6% | +467.0% | -517.7% | -18.4% |
| 3Y | -89.3% | +36.1% | -125.4% | -85.6% |
| 5Y | -94.8% | -68.0% | -26.8% | -93.5% |
| All | -99.9% | +554.4% | -654.3% | -99.7% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling